BOCOM International raised its profit margin and net profit forecasts for Hengrui Pharma due to the company's strong first-quarter performance, which exceeded expectations. The innovative drugs, especially non-oncology products, showed significant growth, contributing over 60% to total sales. The broker considers the current valuation reasonable and has set a target price of HKD74 while maintaining a Neutral rating.
